Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:receptor_tyrosine_kinase
gptkb:drug |
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01EA06
|
| gptkbp:brand |
gptkb:Scemblix
|
| gptkbp:CASNumber |
1492952-76-7
|
| gptkbp:chemicalFormula |
C20H18ClF2N5O3
|
| gptkbp:developer |
gptkb:Novartis
|
| gptkbp:hasSMILES |
CC1=NN(C2=CC=CC=C12)C(=O)NC3=CC=C(C=C3)Cl.C4=CC(=C(C=C4)F)F
|
| https://www.w3.org/2000/01/rdf-schema#label |
asciminib
|
| gptkbp:KEGGID |
gptkb:D11741
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
allosteric inhibitor of BCR-ABL1
|
| gptkbp:molecularWeight |
450.8 g/mol
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL3989989
71661261 DB15323 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
fatigue hypertension pancreatitis myelosuppression |
| gptkbp:target |
BCR-ABL1
|
| gptkbp:UNII |
2ZB08T0Y1V
|
| gptkbp:usedFor |
gptkb:chronic_myeloid_leukemia
|
| gptkbp:bfsParent |
gptkb:Scemblix
|
| gptkbp:bfsLayer |
6
|